Zheng Y, Müller J, Kunz S, Siderius M, Maes L, Caljon G, Müller N, Hemphill A, Sterk GJ, Leurs R. 3-nitroimidazo[1,2-b]pyridazine as a novel scaffold for antiparasitics with sub-nanomolar anti-Giardia lamblia activity.
Int J Parasitol Drugs Drug Resist 2022;
19:47-55. [PMID:
35716585 PMCID:
PMC9213561 DOI:
10.1016/j.ijpddr.2022.05.004]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2022] [Revised: 05/18/2022] [Accepted: 05/20/2022] [Indexed: 11/26/2022]
Abstract
As there is a continuous need for novel anti-infectives, the present study aimed to fuse two modes of action into a novel 3-nitroimidazo[1,2-b]pyridazine scaffold to improve antiparasitic efficacy. For this purpose, we combined known structural elements of phosphodiesterase inhibitors, a target recently proposed for Trypanosoma brucei and Giardia lamblia, with a nitroimidazole scaffold to generate nitrosative stress. The compounds were evaluated in vitro against a panel of protozoal parasites, namely Giardia lamblia, Trypanosoma brucei, T. cruzi, Leishmania infantum and Plasmodium falciparum and for cytotoxicity on MRC-5 cells. Interestingly, selective sub-nanomolar activity was obtained against G. lamblia, and by testing several analogues with and without the nitro group, it was shown that the presence of a nitro group, but not PDE inhibition, is responsible for the low IC50 values of these novel compounds. Adding the favourable drug-like properties (low molecular weight, cLogP (1.2–4.1) and low polar surface area), the key compounds from the 3-nitroimidazo[1,2-b]pyridazine series can be considered as valuable hits for further anti-giardiasis drug exploration and development.
Analogues fusing a nitroimidazole moiety and a PDE inhibitor scaffold were prepared.
These compounds were tested in vitro against a panel of protozoal parasites.
Against Giardia lamblia, sub-nanomolar IC50 values were determined.
PDE inhibition provided no significant contribution to the anti-Giardia potency.
High potency with drug-like properties warrants further study of this hit series.
Collapse